Physicians are turning to other options, including older, cheaper medications, as compounding GLP-1s comes to an end.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for ...

Tirzepatide and semaglutide offer long-term health benefits, but would require discounts to reach $100,000/QALY threshold ...

Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation model. A multifaceted approach is needed to reduce financial barriers to obesity ...

The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list.

LongeVC, an international investor based in Latvia, has injected an unspecified sum into Cambridge company Constructive Bio ...

Tirzepatide and semaglutide, while effective, are not cost-effective due to high prices, negating healthcare savings. Combining antiobesity medications with lifestyle modification improves health ...

Prices would require additional discounts of 30.5 and 81.9 percent for tirzepatide and semaglutide, respectively, from the ...